The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).
The increasing investment and funding by key market players is expected to drive market growth over the forecast period. For instance, in November 2021, Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, announced it had secured an US$87 million in Series A financing led by Syncona Ltd., an investment company. This financing supports the development of the company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells.
Figure 1. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Transplant Type, 2023
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Drivers
Figure 2. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Region, 2023
Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global hematopoietic stem cell transplantation (HSCT) market is expected to witness significant growth in the coming years due to increasing inorganic growth strategies such as mergers to expand their product portfolio in North America region. For instance, in May 2021, Jasper Therapeutics, Inc., a U.S. based biotechnology company focused on hematopoietic cell transplant therapies, announced the merger with Amplitude Healthcare Acquisition Corporation, a private life science company, to provide significant capital to accelerate the development of our two innovative programs: Jasper’s first-in-class clinical-stage anti-CD117 antibody transplant conditioning agent and, in parallel, our groundbreaking research stage Engineered Hematopoietic Stem Cell platform.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
However, the COVID-19 pandemic had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market, owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an American College of Surgeons (ACS) 2021 report, the nature of surgery and anesthesia practices changed during the COVID-19 pandemic as the most elective and non-urgent cases were postponed.
Hematopoietic stem cell transplantation (HSCT) market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients